2 minute read
Redefining the field of flexible endoscopy
Founded in 2003, Creo Medical focuses on the development and commercialisation of minimally invasive devices by bringing Advanced Energy to therapeutic endoscopy. Creo’s first device, Speedboat Inject, is now in use worldwide, providing physicians with new treatment approaches and patients with life-changing outcomes.
Innovative technology to revolutionise surgical endoscopy
Creo’s first device, Speedboat Inject, is part of a suite of miniature endoscopic devices, with a further five receiving regulatory clearance over the past year. Each device is underpinned by groundbreaking research and development, with more than 247 patents granted and a further 763 pending.
Speedboat Inject is a non-invasive device for treatment of tumours in the lower GI tract. With Speedboat, patients are treated under mild sedation rather than requiring invasive surgery with a general anaesthetic. This offers a better patient experience, allows more patients to be treated and can reduce hospital costs.
Unlike other devices on the market, Speedboat Inject uses Advanced Bipolar Energy for dissection and Microwave Energy for coagulation, which means physicians can perform endoscopic surgery with a single device. The difference that Speedboat Inject is making in terms of time, cost and patient outcomes has been recently recognised in a Health Economics study that shows savings of up to £4,294 per treatment under the NHS.
Microwave Energy holds exciting possibilities for minimally invasive tumour ablation
2020 saw the regulatory clearance and first in-patient use of a brand new device for microwave ablation. MicroBlate Fine utilises very high frequency microwave energy, allowing physicians to precisely ablate diseased tissue in multiple organ types and many different clinical access methods. MicroBlate Fine has the same dimensions as a standard biopsy needle, which enables improved access to a wide range of organs (such as pancreas, liver, kidney, lung and muscle) for treatment. The first treatment performed using MicroBlate Fine took place successfully in Ecuador in December 2020. The patient, who had an unresectable pancreatic neuroendocrine tumour, remains well and is enjoying life.
Dr Carlos-Robles-Medranda from Instituto Ecuatoriano de Enferemdades Digestives, Ecuador, said: “I am excited about the potential of this technology for use in EUS guided therapy. The microwave energy allows me to precisely target and ablate difficult lesions. I believe this technology will have a positive impact on my patients, and I will continue to offer this treatment option.”
Partnerships and collaboration provide opportunities to widen impact and treat more patients
Creo Medical has now achieved an international customer base. They sell their technology directly via offices in the UK, the USA and the APAC region and also have routes to market through a channel of certified Distributors globally. The addition of European medical companies Albyn and Boucart to the Creo family over the past year has also opened up new possibilities for partnership and exploring new clinical spaces.
The CROMA Advanced Energy platform, powered by Kamaptive technology, remains the heart of Creo’s technology and has allowed them to develop a range of devices to treat lesions throughout the body.
There’s no reason we can’t use this technology in many applications, whether we’re talking about general surgery, colorectal surgery, urology, OBGYN, you name it. We have the ability to shape the technology based on the unmet clinical needs we’re trying to address. That’s why we call it Kamaptive technology.”
David Woods CCO of Creo Medical